About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Emerging Targets in ER Positive Breast Cancer: CDK4/6 inhibitors, Bcl-2 Inhibitors and PI3K/AKT/mTOR Network
By
Holy Cross 9th Annual Winter Oncology Symposium
FEATURING
Maysa Abu-Khalaf
By
Holy Cross 9th Annual Winter Oncology Symposium
FEATURING
Maysa Abu-Khalaf
615 views
April 23, 2019
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
London Breast Meeting
London Breast Meeting 2024
Wed, Sep 4, 2024
11:31
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, …
Feat.
P. Tarantino
12:35
Insights from 2023 SABCS
SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…
Feat.
S. Tolaney,
H. Rugo
28:36
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "eBC Expert Panel Discussion on Key Trials …
Feat.
H. Rugo,
K. Jhaveri
03:40
Integrity Continuing Education
SABCS 2023 Insights: "CAPItello-291 Trial - Capivasertib & …
Feat.
A. Bardia
17:39
Yale School of Medicine
2023 Menopause Update
Feat.
M. Minkin
17:20
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNO…
Feat.
P. Tarantino
14:16
Dana-Farber Cancer Institute
Year in Review: Breast Cancer
Feat.
P. Tarantino
57:44
Vogl, NY
Vogl,NY on How to Ask Good Questions at Medical Meetings
Feat.
S. Vogl
49:07
SABCS 2022 Conference Coverage
SABCS 2022 Expert Panel Discussion: Practice-Changing Updates
Feat.
J. O'Shaughnessy,
S. Tolaney,
S. Hurvitz,
H. Rugo
10:27
Insights from 2023 SABCS
SABCS 2023 Summary: "What Is the Role for CDK 4/6i in the Adjuv…
Feat.
S. Tolaney,
H. Rugo
07:50
Oncology Data Advisor
ESMO 2023 Insights: "Real-World Use Patterns, Effectiveness, &a…
Feat.
K. Kalinsky
22:34
Dana-Farber Cancer Institute
What's New in Breast Cancer?
Feat.
S. Tolaney
05:43
Total Health
Neoadjuvant Chemo for HR+ BC: Year in Review
Feat.
C. Ma
50:59
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Panel Discussion: "Early Stage Breast Cancer"
Feat.
S. Tolaney,
H. Rugo
17:35
Insights from 2023 SABCS
SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HE…
Feat.
P. Tarantino
23:58
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "mBC Expert Panel Discussion on Key Trials …
Feat.
H. Rugo,
K. Jhaveri
30:46
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Panel Discussion: "Metastatic Breast Cancer"
Feat.
S. Tolaney,
H. Rugo
24:36
ESMO 2022 Conference Coverage
ESMO 2022 Breast Cancer Panel Discussion: Practice-Changing Updates
Feat.
H. Rugo,
J. O'Shaughnessy
24:10
Keck School of Medicine of USC
CDK4/6 Inhibitors in Breast Cancer: 2024 Update
Feat.
R. O'Regan
21:37
Dana-Farber Cancer Institute
Standard Treatments for HR+/HER2- mBC in 2023
Feat.
S. Sammons
